Loading...

PE anti-mouse NK-1.1 Antibody

Pricing & Availability
Clone
PK136 (See other available formats)
Regulatory Status
RUO
Other Names
NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
PK136_PE_NK-11_Antibody_051018
C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and NK1.1 (clone PK136) PE (left) or mouse IgG2a, κ PE isotype control (right).
  • PK136_PE_NK-11_Antibody_051018
    C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and NK1.1 (clone PK136) PE (left) or mouse IgG2a, κ PE isotype control (right).
Compare all formats See PE spectral data
Cat # Size Price Save
108707 50 µg ¥13,420
108708 200 µg ¥31,040
Description

NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References

(PubMed link indicates BioLegend citation)
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sade-Feldman M,et al. 2017. Nat Commun.. 10.1038/s41467-017-01062-w. PubMed
  2. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  3. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  4. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  5. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  6. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  7. Hiyoshi H, et al. 2022. Cell Host Microbe. 30:163. PubMed
  8. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  9. West HC, et al. 2022. Cell Rep. 39:110819. PubMed
  10. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  11. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  12. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  13. Kaltenbach L, et al. 2023. Nat Immunol. 24:915. PubMed
  14. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  15. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  16. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  17. Lee Y, et al. 2020. J Innate Immun. 1:. PubMed
  18. Israelow B, et al. 2020. bioRxiv. . PubMed
  19. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  20. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  21. Zheng M, et al. 2016. Sci Rep. 6:28729. PubMed
  22. Engel O, et al. 2015. Stroke. 46: 3232 - 3240. PubMed
  23. Valencia–Hernandez AM, et al. 2020. Cell Host & Microbe. 27(6):950-962. PubMed
  24. John S, et al. 2020. Sci Rep. 10:11377. PubMed
  25. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  26. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  27. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  28. Adomati T, et al. 2020. Cell Reports. 30(11):3671-3681. PubMed
  29. Hsieh M, et al. 2006. J Immunol. 177:1855. PubMed
  30. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  31. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  32. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  33. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  34. Liu X, et al. 2020. Nature. . PubMed
  35. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  36. Lee AK, et al. 2020. Radiat Res. 193:305. PubMed
  37. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  38. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  39. Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed
  40. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  41. Astrakhan A, et al. 2009. J Immunol. 182:7370. PubMed
  42. Shibata K, et al. 2014. J Immunol. 192:2210. PubMed
  43. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  44. Shemer A, et al. 2020. Immunity. 53(5):1033-1049.e7. PubMed
  45. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  46. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  47. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  48. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  49. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
  50. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  51. Spees A, et al. 2014. Infect Immun . 82:1692. PubMed
  52. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  53. Li J, et al. 2019. JCI Insight. 5. PubMed
  54. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  55. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  56. Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed
  57. Martens CR, et al. 2022. PLoS Pathog. 18:e1010342. PubMed
  58. Zhou Y, et al. 2022. Nat Commun. 13:2906. PubMed
  59. Ruf B, et al. 2021. Cancer Immunol Res. 9:1024. PubMed
  60. McAlpine CS, et al. 2021. Nature. 595:701. PubMed
  61. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  62. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  63. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  64. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  65. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  66. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  67. Galvani E, et al. 2020. Nat Commun. 11:853. PubMed
  68. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  69. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  70. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  71. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  72. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  73. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  74. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  75. Markman JL, et al. 2020. Nat Commun. 11:1613. PubMed
  76. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  77. Kim DH, et al. 2018. Nat Commun. 9:503. PubMed
  78. Li Z, et al. 2018. Front Immunol. 9:347. PubMed
  79. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  80. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  81. Duan B, et al. 2010. J Immunol. 185:335. PubMed
  82. Kadowaki T, et al. 2012. Clin Immunol. 142:296. PubMed
  83. Olson M, et al. 2014. J Immunol. 193:5420. PubMed
  84. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  85. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  86. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  87. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  88. Wu S, et al. 2022. BMC Immunol. 23:17. PubMed
  89. Lang V, et al. 2021. Elife. 10:. PubMed
  90. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  91. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  92. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  93. Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed
  94. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  95. Bachu M, et al. 2019. J Biol Chem. 294:1904. PubMed
  96. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  97. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  98. Yang C, et al. 2016. Sci Rep. 6:34643. PubMed
  99. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  100. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  101. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  102. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  103. Gamrekelashvili J, et al. 2021. Bio Protoc. 11:e4007. PubMed
  104. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  105. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  106. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  107. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
  108. Lokken K, et al. 2014. PLoS Pathog. 10:1004049. PubMed
  109. Hohsfield LA, et al. 2020. J Neuroinflammation. 0.902083333. PubMed
  110. Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed
  111. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  112. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  113. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  114. He B, et al. 2020. Cell Reports. 30(3):714-724.e5.. PubMed
  115. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  116. Okamoto T, et al. 2011. Biomaterials. 32:4925. PubMed
  117. Kitur K, et al. 2015. PLoS Pathog. 11:1004820. PubMed
  118. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  119. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  120. Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed
  121. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  122. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  123. Salazar V, et al. 2019. Cell Rep. 26:1585. PubMed
  124. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  125. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  126. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  127. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  128. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
  129. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  130. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  131. Orr MT, et al. 2019. NPJ Vaccines. 4:1. PubMed
  132. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  133. Zhou X, et al. 2021. Nutr Metab (Lond). 18:64. PubMed
  134. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
  135. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  136. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  137. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  138. Dienz O, et al. 2009. J Exp Med. 206:69. PubMed
  139. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
RRID
AB_313394 (BioLegend Cat. No. 108707)
AB_313394 (BioLegend Cat. No. 108708)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
UniProt
View information about NK-1.1 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All NK-1.1 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse NK-1.1 PK136 FC
Biotin anti-mouse NK-1.1 PK136 FC
FITC anti-mouse NK-1.1 PK136 FC
PE anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
PE/Cyanine7 anti-mouse NK-1.1 PK136 FC
PE/Cyanine5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 488 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 647 anti-mouse NK-1.1 PK136 FC
Pacific Blue™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 711™ anti-mouse NK-1.1 PK136 FC
APC/Cyanine7 anti-mouse NK-1.1 PK136 FC
PerCP anti-mouse NK-1.1 PK136 FC
PerCP/Cyanine5.5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 700 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 421™ anti-mouse NK-1.1 PK136 FC,SB
Brilliant Violet 570™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 650™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 510™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 605™ anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 (Maxpar® Ready) PK136 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 785™ anti-mouse NK-1.1 PK136 FC
APC/Fire™ 750 anti-mouse NK-1.1 PK136 FC
TotalSeq™-A0118 anti-mouse NK-1.1 PK136 PG
Ultra-LEAF™ Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
TotalSeq™-B0118 anti-mouse NK-1.1 PK136 PG
TotalSeq™-C0118 anti-mouse NK-1.1 PK136 PG
PE/Fire™ 810 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 640 anti-mouse NK-1.1 PK136 FC
Spark UV™ 387 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 700 anti-mouse NK-1.1 PK136 FC
Go To Top Version: 3    Revision Date: 05/10/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account